Jeffrey Hubbell to CD4-Positive T-Lymphocytes
This is a "connection" page, showing publications Jeffrey Hubbell has written about CD4-Positive T-Lymphocytes.
Connection Strength
0.403
-
Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses. Biomaterials. 2017 07; 132:48-58.
Score: 0.116
-
Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J Allergy Clin Immunol. 2017 Nov; 140(5):1339-1350.
Score: 0.116
-
Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes. Nat Biomed Eng. 2019 10; 3(10):817-829.
Score: 0.034
-
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 08; 9(415).
Score: 0.030
-
Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials. 2014 Jan; 35(2):814-24.
Score: 0.023
-
Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. Biomaterials. 2013 Jun; 34(17):4339-46.
Score: 0.022
-
Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):E60-8.
Score: 0.022
-
Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. Vaccine. 2012 Dec 14; 30(52):7541-6.
Score: 0.021
-
Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine. 2010 Nov 23; 28(50):7897-906.
Score: 0.019